Investigators found also that higher benefits from the atezolizumab treatment were connected with higher tumour mutational burden (TMB) and PD-L1 expression and worse outcomes detected in patients with high angiogenesis-related gene expression; however, in the ABACUS trial the pCR rate was not increased in TMB-high tumours so further studies are needed [31, 177]. The gene discussed is CD274; the disease is neoplasm.